Antitrust Antitrust

Drugmaker Apotex will pay $24 million to settle cholesterol drug price-fixing charge

By Joshua Sisco
  • 07 May 2020 14:47
  • 07 May 2020 14:47
Florida generic drugmaker Apotex signed a deferred prosecution agreement today with the US Department of Justice and will pay $24.1 million to settle a criminal case over price-fixing of the cholesterol drug pravastatin.
Apotex's three-year DPA was announced by the DOJ (see here). The company is the fourth to settle

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News